Vericel (NASDAQ:VCEL) Upgraded at StockNews.com

StockNews.com upgraded shares of Vericel (NASDAQ:VCEL) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Other analysts have also issued research reports about the stock. Stephens reaffirmed an “overweight” rating and set a $65.00 target price on shares of Vericel in a report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, February 28th. BTIG Research upped their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Truist Financial reiterated a “buy” rating and set a $61.00 price target (down previously from $67.00) on shares of Vericel in a research report on Monday, March 3rd. Finally, Canaccord Genuity Group raised their target price on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $62.29.

Vericel Stock Down 1.4 %

NASDAQ VCEL opened at $48.85 on Friday. Vericel has a 52 week low of $39.12 and a 52 week high of $63.00. The company has a market cap of $2.44 billion, a PE ratio of 814.30 and a beta of 1.78. The firm’s 50-day simple moving average is $56.35 and its two-hundred day simple moving average is $51.99.

Insider Transactions at Vericel

In related news, insider Jonathan Siegal sold 3,908 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the transaction, the insider now owns 1,206 shares in the company, valued at $74,759.94. The trade was a 76.42 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now directly owns 26,595 shares of the company’s stock, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,500 shares of company stock valued at $466,200. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Vericel

A number of large investors have recently made changes to their positions in VCEL. International Assets Investment Management LLC raised its holdings in Vericel by 4,126.7% in the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 619 shares during the period. Arcadia Investment Management Corp MI bought a new position in shares of Vericel in the fourth quarter worth about $48,000. Farther Finance Advisors LLC lifted its position in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Vericel during the 4th quarter valued at about $57,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 1,058 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.